Economic Value of Novel Therapeutics for Chronic Obstructive Pulmonary Disease
Read More
June 2026
Pricing the Next Wave for CVD Secondary Prevention: A Value-Centric Lens based on Historical Market Rewards
A value-anchored price for a novel therapeutic for the secondary prevention of cardiovascular disease that reduces cardiovascular events by 20-30% could range from $4,300 to $9,000 per year.
In this Center for Pharmacoeconomics Spotlight, we calculate historical estimates of payers’ willingness-to-pay for advanced lipid-lowering therapeutics for the secondary prevention of cardiovascular disease.
- Rather than focusing on historical list or net prices, we evaluate the total health system costs relative to the health outcomes gained. This provides a value-centric perspective on how the market has previously valued innovation for the secondary prevention of cardiovascular disease. We then apply this same framework to translate historical willingness-to-pay into value-anchored price ranges that may be relevant for future entrants to the secondary prevention treatment landscape.
- Our analysis suggests that payers have reimbursed advanced lipid-lowering therapies at total health system costs of approximately $110,000 per healthy year gained. This should not be interpreted as the cost-effectiveness of these treatments, but rather the historical willingness-to-pay based on the modeling framework we specified.
- Building on these retrospective insights, we then applied the same modeling framework to estimate value-anchored price ranges for future entrants into the secondary prevention treatment landscape. Read the full report for our value-anchored price ranges based on these historical market rewards.
- These findings provide biotech executives and investors with a differentiated framework to assess value creation, competitive positioning, and potential pricing acceptance for development-stage therapies for the secondary prevention of cardiovascular disease.
For details on obtaining full access to the report, contact us via email at cpe@medacorp.com.
The Leerink Center for Pharmacoeconomics is a division of MEDACorp and an affiliate of Leerink Partners
Leerink Center for Pharmacoeconomics
– Melanie Whittington, PhD, Managing Director, Head of the Center for Pharmacoeconomics
Disclosures
The Center for Pharmacoeconomics (“CPE”) is a division of MEDACorp LLC (“MEDACorp”). CPE is committed to advancing the understanding and evaluating the economic and societal benefits of healthcare treatments in the United States. Through its thought leadership, evaluations, and advisory services, CPE supports decisions intended to improve societal outcomes. MEDACorp, an affiliate of Leerink Partners LLC (“Leerink Partners”), maintains a global network of independent healthcare professionals providing industry and market insights to Leerink Partners and its clients. The information provided by the Center for Pharmacoeconomics is intended for the sole use of the recipient, is for informational purposes only, and does not constitute investment or other advice or a recommendation or offer to buy or sell any security, product, or service. The information has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice, and any opinions and information contained herein are as of the date of this material, and MEDACorp does not undertake any obligation to update them. This document may not be reproduced, edited, or circulated without the express written consent of MEDACorp.
© 2026 MEDACorp LLC. All Rights Reserved.
Disclosures
The Center for Pharmacoeconomics (“CPE”) is a division of MEDACorp LLC (“MEDACorp”). CPE is committed to advancing the understanding and evaluating the economic and societal benefits of healthcare treatments in the United States. Through its thought leadership, evaluations, and advisory services, CPE supports decisions intended to improve societal outcomes. MEDACorp, an affiliate of Leerink Partners LLC (“Leerink Partners”), maintains a global network of independent healthcare professionals providing industry and market insights to Leerink Partners and its clients. The information provided by the Center for Pharmacoeconomics is intended for the sole use of the recipient, is for informational purposes only, and does not constitute investment or other advice or a recommendation or offer to buy or sell any security, product, or service. The information has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice, and any opinions and information contained herein are as of the date of this material, and MEDACorp does not undertake any obligation to update them. This document may not be reproduced, edited, or circulated without the express written consent of MEDACorp.
© 2026 MEDACorp LLC. All Rights Reserved.
Disclosures
The Center for Pharmacoeconomics (“CPE”) is a division of MEDACorp LLC (“MEDACorp”). CPE is committed to advancing the understanding and evaluating the economic and societal benefits of healthcare treatments in the United States. Through its thought leadership, evaluations, and advisory services, CPE supports decisions intended to improve societal outcomes. MEDACorp, an affiliate of Leerink Partners LLC (“Leerink Partners”), maintains a global network of independent healthcare professionals providing industry and market insights to Leerink Partners and its clients. The information provided by the Center for Pharmacoeconomics is intended for the sole use of the recipient, is for informational purposes only, and does not constitute investment or other advice or a recommendation or offer to buy or sell any security, product, or service. The information has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice, and any opinions and information contained herein are as of the date of this material, and MEDACorp does not undertake any obligation to update them. This document may not be reproduced, edited, or circulated without the express written consent of MEDACorp.
© 2026 MEDACorp LLC. All Rights Reserved.
